Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 3/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559571 | 0.85 | SLC16A3 (0.83) | SLC16A3PLK1PLK3 | |
| SCHEMBL3556329 | 0.85 | SLC16A3 (1.00) | SLC16A3PLK1PLK3 | |
| SCHEMBL3557242 | 0.84 | SLC16A3 (0.73) | SLC16A3L3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3564050 | 0.84 | SLC16A3 (1.00) | SLC16A3ALDH1A1HPGDPOLBPLK1 | |
| SCHEMBL3561727 | 0.82 | SLC16A3 (1.00) | SLC16A3ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL3555542 | 0.81 | SLC16A3 (0.68) | SLC16A3ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL3554752 | 0.81 | SLC16A3 (0.68) | SLC16A3L3MBTL1PLK1PLK3TP53 | |
| SCHEMBL3559656 | 0.81 | SLC16A3 (0.69) | SLC16A3L3MBTL1PLK1PLK3TP53 | |
| SCHEMBL3562667 | 0.80 | SLC16A3 (1.00) | SLC16A3PLK1PLK3 | |
| SCHEMBL3557763 | 0.80 | SLC16A3 (0.78) | SLC16A3PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885L3MBTL1 2080/4885ALDH1A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.